Literature DB >> 10494350

The frequency, antecedent events, and causal relationships of neurologic worsening following severe head injury. Executive Committee of the international Selfotel Trial.

A Ananda1, G F Morris, N Juul, S B Marshall, L F Marshall.   

Abstract

Neurologic deterioration observed following head injury is recognized as having a deleterious effect on outcome. The present study examines this occurrence in detail to determine the frequency of these episodes, their antecedent events and causal relationships in order to identify patients who are at risk. Data was collected prospectively from a consecutive series of 427 patients entered into the international trial of the NMDA receptor antagonist Selfotel. Using a definition of neurologic worsening based upon objective criteria, 117 patients were identified who suffered 164 episodes of deterioration. The occurrence of a single episode of neurologic worsening increased mortality by more than five-fold and reduced favorable outcomes (good or moderate on the Glasgow Outcome Scale), by more than 50%. Increased intracranial volume resulting in intracranial hypertension was the single most frequent cause of neurologic worsening. This serves to emphasize the importance of more adequate treatments of intracranial hypertension in improving the outcome of patients with severe head injury.

Entities:  

Mesh:

Year:  1999        PMID: 10494350     DOI: 10.1007/978-3-7091-6391-7_17

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  2 in total

Review 1.  Brainstem Monitoring in the Neurocritical Care Unit: A Rationale for Real-Time, Automated Neurophysiological Monitoring.

Authors:  James L Stone; Julian E Bailes; Ahmed N Hassan; Brian Sindelar; Vimal Patel; John Fino
Journal:  Neurocrit Care       Date:  2017-02       Impact factor: 3.210

Review 2.  Excitatory amino acid inhibitors for traumatic brain injury.

Authors:  C Willis; S Lybrand; N Bellamy
Journal:  Cochrane Database Syst Rev       Date:  2004
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.